Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.

CSE:SONA - Post by User

Sona Nanotech Inc

Bullboard Posts

Comment by sanddevilon Jul 25, 2020 10:36pm

217 Views

Post# 31319934

RE:RE:RE:RE:RE:Field Tests

no They don't Why would they need to come back better ?! Anything over 80-85% is great They came in near 97% This field trial will come in about same or slightly worse or slightly better

TheeRook wrote: Actually the filed numbers need to come back better than the MRI global data.

From (29/30) & ( 28/29) to at least (29 / 30) & (29 / 29)

Validation studies were also conducted in house to assess potential clinical performance of the test using 30 nasopharyngeal samples from healthy individuals who were presumed negative for COVID-19. Results from the study generated a specificity of 96 per cent (29/30) and a sensitivity of 96 per cent (28/29). All specimen samples tested generated negative results, except for one, generating the result of 96 per cent. To generate the sensitivity data, the remnants of each negative sample were spiked with gamma-irradiated COVID-19 virus and the tests rerun to determine the positive results, generating the result of 96 per cent.

dart321 wrote: When the field tests come back like the MRIGrobal numbers because I have confidence they will be close, when they release those numbers I will do an analytic share price estimate based on sector multiples not industry standard multiples. Don't want to say much until the proof is in the pudding.